Clinical trial Recruiting at 1 site Observational Ages 65 to 100

Studying cancer drug effectiveness and safety in elderly patients

Official title: Population Pharmacokinetics, Effectiveness and Safety of Antineoplastic Drugs in Elderly Patients

Run by Shandong University · NCT05467189 · Data updated 2026-11-12

This study is testing how well and safely different cancer drugs work for older patients aged 65 and up to help improve their treatment.

More Breast Cancer trials

Quick facts

Study typeObservational
Ages65 Years to 100 Years
SexAll
Enrollment500 (estimated)
SponsorShandong University
Academic / other
Drugs / interventionsAfatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib
Locations1 site (Jinan, Shandong)
StatusRecruiting
StartedJanuary 1, 2021
Main results expectedMarch 30, 2028
Study endsJune 30, 2028
Registry record updatedJuly 20, 2022
Trial IDNCT05467189 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are elderly patients aged 65 and older who have been diagnosed with cancer and are currently using antineoplastic drugs.

Probably not a fit

Patients who are expected to die within 48 hours or have allergies to antineoplastic drugs will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the population pharmacokinetics, effectiveness, and safety of various antineoplastic drugs, including Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, and Lapatinib, specifically in elderly patients aged 65 and older diagnosed with cancer. The study will analyze how these drugs behave in this population and recommend optimized dosage regimens to enhance treatment outcomes. By focusing on the elderly, the study addresses a critical gap in cancer treatment, as this demographic often responds differently to medications compared to younger patients.

Why it matters

Potential benefit: If successful, this study could lead to more effective and safer cancer treatments tailored for elderly patients.

How similar studies have gone: While there is ongoing research into cancer treatments for the elderly, this specific focus on population pharmacokinetics and optimized dosing regimens for a range of antineoplastic drugs is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be enrolled in the study:

1. Age ≥65 years old;
2. Diagnosed with cancer;
3. Using antineoplastic drugs for treatment.

Exclusion Criteria:

Subjects with any of the following criteria will not be enrolled in this study:

1. Patients who are expected to die within 48 hours;
2. Patients with allergy to antineoplastic drugs;
3. Patients receiving other investigational drugs;
4. Other factors that the researcher considers unsuitable for inclusion.

Where it's running

  • Shandong Provincial Qianfoshan Hospital
    Jinan, Shandong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.